From PEGylation to Bioactive Proteins: Advancing Drug Half-Life Extension

0
395

Macromolecular proteins and peptides have proven to be highly effective in treating serious human diseases. Over the past few decades, advancements in biotechnology have led to the development of numerous authorized protein therapeutics and drug products, which are now widely used in clinical research. However, a major challenge for protein therapeutics remains their short half-lives, primarily caused by rapid degradation in serum and swift elimination during clinical use. This is due to factors such as enzymatic degradation, renal clearance, liver metabolism, and immunogenicity.

 

In response to this challenge, researchers have made significant progress in developing strategies to extend the half-lives of protein therapeutics and biopharmaceutical products. One such approach is the use of polymers for drug half-life extension. Polymer conjugation, particularly PEGylation, has emerged as an efficient and widely used technique. PEGylation enhances pharmacokinetic properties by providing highly hydrophilic and largely non-toxic characteristics, making it a valuable tool in drug development.

 

As protein engineering technology evolves, bioactive natural protein conjugation has gained recognition as a promising strategy for prolonging drug half-lives, offering reduced toxic side effects. Various bioactive natural protein conjugation technologies are currently being developed, including:

 

Albumin-based half-life extension: Albumin conjugation is already widely used in several protein drugs available on the market.

Fc-Fusion-based half-life extension: The Fc-Fusion technique is highly effective for modifying most therapeutic proteins.

Transferrin fusion-based half-life extension: Transferrin fusion is an innovative approach with potential for clinical application in extending drug half-lives.

Moreover, the lack of efficacy remains a primary cause of drug candidate attrition. Drug half-life assays are essential in drug development as they determine the half-life of drugs, serving as the first critical step in selecting suitable candidates for clinical trials. To address this need, many contract research organizations (CROs) are offering advanced assay services. Creative Biolabs, for example, has developed a comprehensive half-life assay platform, providing high-quality in vitro and in vivo detection services for drug half-life evaluation.

 

As a leading global CRO specializing in drug development, Creative Biolabs has accumulated extensive experience in half-life extension, earning a strong reputation among clients worldwide. The companys scientists continue to refine its half-life extension technologies, ensuring the delivery of optimal services to accelerate the progress of drug development.

Căutare
Sponsor
Title of the document
Sponsor
ABU STUDENT PACKAGE
Categorii
Citeste mai mult
Causes
Unlocking Precision: The Rare Breed Trigger Advantage for AR-15 Enthusiasts
For AR-15 enthusiasts seeking to enhance their shooting experience, the Rare Breed Trigger...
By Ahsan Seo 2025-04-11 13:47:45 0 227
Alte
Ethernet Switch Market Leading Players ,Size, Share , Analysis And Regional Forecast 2030
Ethernet Switch Market Overview As per market research, the total Ethernet...
By Chetanag Gardas 2024-09-18 17:35:46 0 1K
Alte
Medical Devices Testing Services Market Share, Size, Global Driving Factors by Manufacturers, Growth Opportunities Forecast to 2030
The latest research report by Emergen Research, named ‘Global Medical Devices Testing...
By Prathamesh Gavade 2023-03-29 09:53:00 0 5K
Film
Indian influencer Sapna Shah leak video all parts utb
🌐 CLICK HERE 🟢==►► WATCH NOW 🔴 CLICK HERE 🌐==►► Download Now...
By Guifet Guifet 2025-03-10 17:10:39 0 279
Home
Indoor Swimming Pool Heat Pump Installation vs. Outdoor: Which Offers Better Energy Efficiency?
When it comes to heating swimming pools, heat pumps have emerged as a popular and...
By Oakley Clark 2023-10-25 07:02:05 0 3K